Pazopanib for non-clear cell variant of kidney cancer – pro
There is no standard of care treatment for the rare papillary variant of renal cell cancer. Unfortunately, nothing is known about this combination for non-clear cell variants of kidney cancer. A recent review (Gupta et al) says: “There is lack of prospective, randomized data pertaining to the efficacy of VEGF-TKIs in the treatment of non-clear-cell mRCC, although some data from the expanded access programs suggest that the VEGF TKIs sorafenib and sunitinib may have some activity in this subgroup of patients, as these tumors overexpress c-kit and these drugs target c-kit [Gore et al. 2009; Stadler et al. 2010]. Given that pazopanib is an inhibitor of c-kit as well, its efficacy in non-clear-cell mRCC is being explored in a phase II trial [ClinicalTrials.gov identifier: NCT01538238]. The results from these studies would further clarify whether pazopanib has a role in this subgroup of patients with mRCC.”
Sylvie Negrier, Diane Charlotte Imbs, David Pérol, Ratislav Bahleda, Antoine Hollebecque, Helen Jane Boyle, Celine Ferlay, Severine Metzger, Ellen Blanc, Jean-Charles Soria, Bernard J. Escudier, Etienne Chatelut; Léon-Bérard Cancer Centre, Lyon, France; Institut Claudius Regaud, Toulouse, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Institut Gustave Roussy, INSERM U981, Villejuif, France. Pazopanib (P) and bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors: Phase I combination study final analysis. J Clin Oncol 31, 2013 (suppl; abstr 4574)
Shilpa Gupta and Philippe E. Spiess, The prospects of pazopanib in advanced renal cell carcinoma. T her Adv Urol. 2013 Oct; 5(5): 223–232.